Medpace leads a rally in CRO space after Q2 beat
Seeking Alpha ·
Shares of Medpace Holdings ( MEDP ) climbed, and its rival contract research organizations also traded higher after the company reported Q2 2026 financials and provided full-year guidance exceeding Street forecasts. Medpace ( MEDP ) added more than 15%, recording its best intraday rally
DYAX Investor Sentiment
Bullish (Long) 54% · Bearish (Short) 46%
418 participants
Related News
- First Citizens projects $6B-$8B FDIC note paydown in Q3 2026 backed by BMO branch acquisition
- Trump weighs larger military strikes on Iran - reports
- Google, Amazon, Meta, & Microsoft will spend 'unprecedent' $1T on AI capex in 2027: Analyst
- Indra Sistemas, S.A. reports 1H results
- Origin Bancorp anticipates high single-digit net interest income growth as it targets at least 1.15% ROA in Q4
- United Rentals outlines 2026 revenue of $17.5B-$17.8B while raising adjusted EBITDA view to $7.975B-$8.125B
